Comerica Bank lowered its stake in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 7.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,817 shares of the biotechnology company’s stock after selling 2,730 shares during the quarter. Comerica Bank’s holdings in GRIFOLS S A/S were worth $699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Advisors Asset Management Inc. raised its stake in GRIFOLS S A/S by 40.8% in the first quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 1,479 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of GRIFOLS S A/S by 9.1% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,296 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 526 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of GRIFOLS S A/S in the first quarter worth about $240,000. Wetherby Asset Management Inc. raised its stake in shares of GRIFOLS S A/S by 5.5% in the second quarter. Wetherby Asset Management Inc. now owns 16,189 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 849 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of GRIFOLS S A/S by 24.8% in the second quarter. Quadrant Capital Group LLC now owns 20,324 shares of the biotechnology company’s stock worth $422,000 after purchasing an additional 4,033 shares during the last quarter. 17.99% of the stock is currently owned by institutional investors.
GRFS has been the topic of several analyst reports. BidaskClub lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research raised GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Monday. JPMorgan Chase & Co. raised GRIFOLS S A/S from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $22.50 in a report on Thursday, June 27th. Finally, ValuEngine lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $20.75.
NASDAQ:GRFS traded down $0.41 on Friday, reaching $20.31. The company’s stock had a trading volume of 213,927 shares, compared to its average volume of 1,296,572. The company has a quick ratio of 0.95, a current ratio of 2.68 and a debt-to-equity ratio of 1.38. The firm has a market cap of $14.19 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.27 and a beta of 1.11. GRIFOLS S A/S has a 12-month low of $17.42 and a 12-month high of $23.03. The stock has a 50 day moving average price of $21.76 and a 200 day moving average price of $20.08.
GRIFOLS S A/S (NASDAQ:GRFS) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $0.33 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. The firm had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. GRIFOLS S A/S had a return on equity of 14.88% and a net margin of 11.82%. Equities research analysts expect that GRIFOLS S A/S will post 1.23 EPS for the current fiscal year.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Further Reading: Why does a company issue an IPO?
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.